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Sixty-three postmenopausal women with large primary breast cancers were treated with neoadjuvant letrozole (2.5mg daily) for 3
months. Tumour samples were taken at diagnosis and after 10–14 days and 3 months treatment. Immunohistochemical staining for
Ki67, oestrogen receptor (ER) and progesterone receptor (PgR) was performed and related to clinical (ClinR) and pathological
responses (PathR) after 3 months treatment. ClinR was observed in 48 of 63 cases (76.2%) and PathR in 47 of 62 (75.8%).
Pretreatment Ki67 scores were similar in responders (R) and non-responders (NR). Highly significant Ki67 decreases occurred in all
tumour subgroups at 10–14 days (Po0.005). A significant difference in Ki67 scores at 10–14 days (Po0.007) was found between
PathR and PathNR but not between ClinR and ClinNR. At 3 months, decreases from pretreatment Ki67 scores were highly significant
in all tumour subgroups irrespective of response status. However, whereas Ki67 scores were significantly different between
pathological R and NR (P¼0.009), the corresponding comparison of ClinR status was not. Significant decreases between 10–14 days
and 3 months were found only in ClinR and PathR (P¼0.02 and 0.045, respectively). Treatment significantly reduced PgR expression
at 14 days and 3 months (both Po0.0001), but the level of changes was not different between response status groups. In summary,
letrozole produces rapid and profound decreases in expression of Ki67 and PgR but changes do not always correlate with clinical and
pathological responses.
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Letrozole is a third-generation aromatase inhibitor, which in
clinical trials has been shown to be highly effective in post-
menopausal women with oestrogen receptor (ER)-positive breast
cancer (Eiermann et al, 2001; Mouridsen et al, 2001; Goss et al,
2003; Rose et al, 2003). Previous studies using neoadjuvant therapy
have shown that letrozole may produce profound changes in
tumour pathology and immunohistochemical markers (Dixon
et al, 2001; Ellis et al, 2001, 2003; Miller et al, 2003; Anderson et al,
2004). Furthermore, it is clear that the clinical effects of
neoadjuvant treatment with third-generation aromatase inhibitors
in postmenopausal women are not dissimilar to those seen with
neoadjuvant chemotherapy (Dixon et al, 2001) and are achieved
with less morbidity. Comparative studies have also shown that the
effects of third-generation aromatase inhibitors are more consis-
tent and greater than tamoxifen on proliferation (as measured by
Ki67) and markers of oestrogen action (progesterone receptors
(PgR) and trefoil factor 1) (Ellis et al, 2003; Miller et al, 2003;
Anderson et al, 2004). It is therefore interesting that in the
neoadjuvant setting, letrozole yields significantly superior clinical
results than tamoxifen and also appears to be more effective in
particular subgroups such as tumours with low ER levels and
overexpression of HER-2 (Ellis et al, 2001). However, the timescale
of these effects and their relationship to clinical and pathological
response as assessed at the end of treatment has yet to be fully
defined. The aim of the present study was therefore to assess the
effects of letrozole on the proliferation marker Ki67 and receptors
for oestrogen and progesterone by immunohistochemical assess-
ment in serial biopsies from primary breast cancers taken before,
at 10–14 days and at 3 months into treatment.
MATERIALS AND METHODS
Patients
A total of 63 postmenopausal women presented to the Edinburgh
Breast Unit with large (43cm) primary breast cancer, which were
ER-rich (Allred score 5–8). (However, review of the cases in the
research laboratory showed that all patients recruited to the study
had ER scores of 7 or 8.) All patients apart from 12 were technically
operable. The primary clinical objective was to downstage tumours
such that those who were inoperable became amenable for surgery
and those who would have required mastectomy could become
candidates for breast conservation. This series represents con-
secutive patients recruited but excluding cases in which the
tumour was shown to be multifocal or of special histological type
(e.g. mucinous, tubular/cribriform and lobular). All patients gave
informed consent to be included in the study, which had been
approved by the local ethics committee (2001/W/BU/09 and 2001/
W/BU/10).
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All patients received letrozole (2.5mg, daily) for 3 months. Serial
measurements of the primary tumours were taken before, at 6
weeks and at 3 months by calliper and ultrasound as described
previously (Forouhi et al, 1994; Dixon, 2001). The tumour was also
imaged mammographically before and at 3 months. Core biopsies
were taken at the start, after 10–14 days and at 3 months of
treatment as described previously (Iqbal et al, 2002). All patients,
apart from eight patients (who electively continued on treatment),
received definitive surgery at 3 months.
Response assessment
Tumour volumes were determined from ulstrasound measure-
ments as described by Forouhi et al (1994). Reduction in volume
over a 3 month period 450% was regarded as clinical response;
this includes both complete and partial responders.
Pathological response was determined by comparing biopsies
taken before and after 3 months of treatment. Only marked
reduction in cellularity and/or a clear increase in fibrosis were
used as evidence of pathological response. Although these changes
are essentially subjective, they were confirmed by two observers
working independently. The criteria may underestimate actual
morphological changes occurring to a lesser degree, but these were
excluded because of the difficulty in comparing histological
appearances on limited tissue such as in core biopsies with those
in the more substantial material obtained at tumour excision. No
case was classified as a complete PathR, residual evidence of
malignant cells being evident.
Immunohistochemistry
Immunohistochemistry staining with antibody to MIB1 (Ki-67)
antigen (Europath Ltd, Cornwall, UK) diluted  50 was used as
a measure of tumour cell proliferation. Reactivity was detected by
an ABC–peroxidase–antiperoxidase (PAP) method, and scored
according to the method described by Going (1994). A change of
440% between different paired biopsies was taken as being
meaningful (Ellis et al, 1998; Iqbal et al, 2002) and a value of o1%
was regarded as indicating a lack of proliferation.
Reactivity for ER or PgR was performed by the PAP method,
after microwave antigen retrieval, using ERa antibody clone 6f11/2
(Novocastra Ltd, Newcastle, UK) and PgR antibody clone PgR636
(DAKO Labs, Ely, UK) using the DAKO EnVision system
according to the manufacturer’s instruction. Results were scored
on a scale of 0–3 for staining intensity (with each successive
score denoting increasing intensity), and on a score of 0–5 for
increasing proportion of positive cancer nuclei (0¼none,
1¼o1%, 2¼1–10%, 3¼11–33%, 4¼34–66%, 5¼466%).
The values were then summed into a category score within a
range of 0–8 (Allred et al, 1998).
Statistics
Non-parametric comparisons using either Wilcoxon rank or
Spearman paired testing was employed and, where appropriate,
3 2 w
2 testing.
RESULTS
Clinical and pathological response
Of the 63 patients, 48 (76.2%) were classified as clinical responders
(ClinR). With regard to pathological response, one case was not
assessable because of insufficient material after biopsy at 3
months. Of the remaining 62 cases, 47 (75.8%) had clear evidence
of pathological response. Although response rates were similar,
there was not exact concordance between clinical and pathological
outcomes. Thus, 42 of 48 ClinR were also pathological responders
(PathR) (six were pathological non-responders (PathNR)) and
nine of 15 clinical non-responders (ClinNR) were also PathNR. Of
the remaining six cases, five were PathR and one case was
pathologically not assessable.
Proliferation (Ki67)
The tumour Ki67 scores for pretreatment, 10–14 days and 3
months samples, subdivided according to clinical and pathological
response status, are shown in Table 1.
No significant differences were apparent for pretreatment group
scores between responders (R) and non-responders (NR) whether
assessed clinically or pathologically. However, at 10–14 days,
whereas there was no difference between ClinR and ClinNR, the
PathNR were significantly higher than PathR (P¼0.024). Similarly
at 3 months, although there was no significant difference between
ClinR and ClinNR, values in PathNR were significantly higher than
in PathR (P¼0.009).
With regard to group changes in Ki67 with treatment, the scores
at 10–14 days and 3 months were highly significantly decreased, as
compared with those in paired pretreatment biopsies. These
changes were irrespective of clinical or pathological response
status. In terms of changes occurring between 10–14 days and 3
months, a significant decrease was seen in ClinR (P¼0.02) and
PathR (P¼0.045). However, values were not significantly different
between 10–14 days and 3 months in ClinNR and PathNR.
Changes in Ki67 with treatment in individual tumours are
summarised in Table 2. In terms of 440% change criteria for
ClinR, 52 of 63 cases (82.5%) showed a decrease at 10–14 days,
and 53 of 63 tumours (84%) showed a reduction at 3 months.
These reductions were seen in both ClinR and ClinNR groups, and
there was no significant difference between them. However, for
pathological assessments, there was a significant difference
between PathR and PathNR at 10–14 days (P¼0.034) but not at
3 months. Treatment effects were also assessed on the basis of
reducing Ki67 scores to o1%. It can be seen that whereas 11 cases
(17.5%) were reduced to o1% by 10–14 days, these numbers
markedly increased to 27 (42.9%) by 3 months. Whereas the
reduction to o1% was seen in both responding and non-
responding tumours, the increase in numbers between 10–14
days and 3 months is predominantly associated with responding
tumours.
Different patterns of changes in Ki67 over the treatment period
could be detected. These are shown in Figure 1. The largest cohort
of tumours (47) showed substantial decreases at 10–14 days,
which were maintained or fell further at 3 months (in these
tumours, changes in Ki67 at 10–14 days were predictive of those at
3 months). However, there was a small cohort of five patients in
which a decrease at 10–14 days was followed by a substantial rise
Table 1 Ki67 scores in tumour taken before and after 10–14 days and 3
months of treatment, subdivided according to response status
Ki67 scores (mean7s.e.m.)
Pretreatment 10–14 days 3 months
Clinical responders (48) 14.1771.10 5.1170.98
+ 4.1370.96
+,~
Clinical non-responders (15) 15.2972.06 6.7272.04
+ 5.8571.91*
,1
P¼0.70 P¼0.77 P¼0.13
Pathological responders (47) 14.0371.09 4.027085
+ 3.4770.90
+,~~
Pathological non-responders (15) 15.9772.22 9.3572.22** 8.1172.01***
,1
P¼0.52 P¼0.024 P¼0.009
Compared with pretreatment tumour:
+Po0.0001; *P¼0.003; **P¼0.007;
***P¼0.009. Compared with tumour taken after 10–14 days of treatment:
~P¼0.02;
~~P¼0.045: 1P¼NS.
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sin score at 3 months (in these tumours, changes in Ki67 at 10–14
days did not therefore concur with those at 3 months). Of the 11
that did not decrease at 10–14 days, six decreased at 3 months
(Ki67 changes therefore did not concur at 10–14 days and 3
months) and five were not reduced at 3 months (lack of change in
Ki67 at 10–14 days was predictive of no change at 3 months).
These patterns of Ki67 did not correlate with ClinR and PathR
phenotype (Figure 2).
Progesterone receptors
Of the 63 cases, 57 (90%) were PgRþve; of the six negatives, five
were ClinR and four were PathR. The changes with treatment of
PgR staining subdivided according to ClinR and PathR status are
summarised in Table 3.
Treatment reduced PgR scores such that, at 10–14 days, values
were significantly lower than those in the paired pretreatment
biopsy (Po0.0001). This decrease was found in all tumour
subgroups irrespective of clinical or pathological assessment
status. Similar highly statistically significant decreases were also
seen when pretreatment values were compared with corresponding
pairs at 3 months (Po0.0001). Of note is the high proportion of
positive tumours that decreased to 0 by 10–14 days (45.6%). This
percentage rose to 66.7% at 3 months. A comparison of 10- to 14-
day biopsies with those at 3 months showed significant decreases
with extended treatment with the groups of ClinR and PathR,
whereas no significant difference was detected in the NR group
Table 2 Changes in tumour Ki67 scores with treatment
No. of patients
Changes at 10–14 days Changes at 3 months
Increase No change
Decrease
Increase No change
Decrease
by 40% to o1% by 40% o1%
Clinical responders (48) 1 6 41 (8) 0 7 41 (23)
Clinical non-responders (15) 1 3 11 (3) 1 2 12 (4)
Total 2 9 52 (11) 1 9 53 (27)
P¼0.49 P¼0.20
Pathology responders (47) 1 4 42 (9) 0 6 41 (23)
Pathology non-responders (15) 1 5 9 (2) 1 3 11 (3)
Total 2 9 51 (11) 1 9 52 (26)
P¼0.034 P¼0.15
Statistical comparison of increase (440%), decrease (440%) or no change (o40%) compared with pretreatment values by 3 2 chi-square testing.
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Figure 1 Tumour Ki67 scores before and after 10–14 days and 3 months treatment with letrozole. (A) Cases that show decreases (440%) at both 10–
14 days and 3 months. (B) Cases that show decreases (440%) at 10–14 days but not at 3 months. (C) Cases that show no change at 10–14 days but a
decrease (440%) at 3 months. (D) Cases that show no decrease at either 10–14 days or 3 months.
Letrozole, proliferation and response in breast cancer
WR Miller et al
1053
British Journal of Cancer (2006) 94(7), 1051–1056 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
s(but this represents a small number of pairs). In terms of
comparisons between tumours R or NR assessed either clinically
or pathologically, no significant differences were detected either at
pretreatment, 10–14 days or 3 months in absolute values (data not
shown).
Oestrogen receptors
There was no significant difference in ER score pretreatment, after
10–14 days and after 3 months. Neither was there a significant
change with treatment with all biopsies scoring 7 or 8 throughout
(data not shown).
DISCUSSION
The observation that neoadjuvant treatment with letrozole is
associated with a marked reduction in the immunohistochemical
expression of Ki67 and PgR confirms our previous findings (Miller
et al, 2003; Anderson et al, 2004) and those of others (Ellis et al,
2001, 2003). However, the present study extends our previous work
by demonstrating that such effects are evident as early as 10–14
days into treatment in over 80% of cases. Similar results have
recently been presented for anastrozole (Dowsett et al, 2005a,b).
The same group have also presented results from a randomised
neoadjuvant trial comparing the aromatase inhibitor vorozole with
tamoxifen. Ki67 levels fell within 2 weeks of treatment and
remained suppressed at surgery 3 months later (Harper-Wynne
et al, 2002). These effects are therefore apparent before evidence of
morphological changes in tumour pathology and clinical evidence
of changes in tumour volume. It was of interest in the present
paper to determine whether changes in proliferation and PgR
expression related to and/or predicted for subsequent ClinR and
PathR.
In terms of assessing proliferation status with Ki-67 scores, we
have analysed results in three ways: (i) comparison of tumour
scores at individual time points grouped according to response
status at 3 months, (ii) classifying a 440% change in Ki-67
between different time points as evidence of a meaningful change
in proliferation and (iii) comparing the number of cases in which
proliferation is reduced to o1%, a value that we have regarded as a
state of virtual non-proliferation. By using these multiple analyses,
we hoped to derive impressions not only of group trends but
effects and degree in individual cases.
Group comparisons of mean Ki-67 scores at individual study
time points revealed interesting differences according to whether
response was assessed clinically or pathologically. Thus, the only
detectable significant differences were in groups subdivided by
pathological assessment in which higher mean scores were found
in non-responding tumours at both 10–14 days and 3 months.
Interestingly, the same general pattern was evident when
categorising individual cases according to 440% reduction (the
only significant difference was seen between PathR and PathNR at
10–14 days). The restriction of significant effects to pathological
assessment probably reflects the closer association between two
histological assessments rather than that between histology and
tumour size. It is also worth noting that the tumour morphology
after treatment will be determined by factors in addition to
proliferation, such as cell loss. In this respect, although Ki67 is a
primary marker of proliferation, it can also be a secondary
reflection of cell death (Archer et al, 2003).
A reduction of 440% in Ki-67 was apparent in most cases at
10–14 days, and extended treatment to 3 months was associated
with only minor changes in the proportion of tumours that
displayed a 440% decrease in proliferation. This is in contrast to
the results based upon the more profound criteria of a decrease to
an absolute value of o1%. These results show that, remarkably,
even after 10–14 days of treatment, 17% of tumours have reached
this state of virtual non-proliferation, and this was irrespective of
whether tumours subsequently displayed evidence of clinical or
pathological response. However, the proportion of cases falling
to o1% proliferation increases further to 43% by 3 months.
Interestingly, this incremental effect with time appears restricted
to those tumours that had either a pathological or clinical response
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Figure 2 Flow diagram indicating number of cases grouped according to
Ki67 changes at 10–14 days and 3 months and further subdivided
according to final clinical/pathological response.
Table 3 Changes in tumour PgR score with treatment
No. of patients
Changes at 10–14 days Changes at 3 months
Increase No change Decrease (Decrease to 0) Increase No change Decrease (Decrease to 0)
Clinical responders (48) 1 11 36 (18) 0 9 39 (29)
Clinical non-responders (15) 0 2 13 (8) 0 2 13 (9)
Pathology responders (47) 1 11 35 (16) 0 9 38 (26)
Pathology non-responders (15) 0 2 13 (9) 0 2 13 (11)
PgR¼progesterone receptor.
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sstatus at 3 months. It is clear that letrozole is capable of producing
increased suppression of proliferation when used over an extended
period.
The overall perspective therefore is that letrozole is capable of
producing a rapid reduction in tumour proliferation that is seen in
most tumours irrespective of subsequent clinical and pathological
response, but that incremental effects on proliferation (as
monitored by scores of o1%) are additionally seen in the period
between 10–14 days and 3 months, and these are largely restricted
to PathR or ClinR.
Whereas changes in Ki-67 levels have been revealed by group
comparisons, the strength of neoadjuvant studies is that it is
possible to examine differences in individual cases and classify
tumours according to sequential changes in proliferation. Thus,
consistent with the general trends discussed above, most tumours
displayed a substantial decrease in proliferation 440% by 10–14
days and this was sustained at 3 months. However, it was also
possible to identify (i) a small cohort that initially had decreased
proliferation at 10–14 days but which largely disappeared by 3
months, (ii) tumours that failed to demonstrate a decrease in
proliferation at 10–14 days but had a delayed decrease apparent
at 3 months and (iii) cases that failed to display a decrease in
proliferation at both 10–14 days and 3 months. It is therefore
important not only to discuss relationships between clinical/
pathological response and proliferation at individual time points,
but also to take into account the patterns of change in response to
treatment.
Statistically significant differences were detected between PathR
and PathNR in (i) group levels of Ki67 at 10–14 days and (ii) the
proportion of cases decreasing in Ki67 440% between pretreat-
ment and 10–14 days. However, there was a large overlap in values
at 10–14 days between PathR and PathNR, and individual tumours
could display an increase, no change or a decrease in Ki67
irrespective of being PathR or PathNR. Consequently, measure-
ments of Ki67 in individual cases do not accurately predict for
subsequent pathological (or clinical) response. A similar lack of
prediction between Ki67 changes and clinical response to
anastrozole has been observed in the recently reported IMPACT
neoadjuvant trial (Dowsett et al, 2005a) (although the short-term
changes in proliferation did parallel recurrence-free survival
between the three treatment groups, anastrozole, tamoxifen and
Arimidex combined with tamoxifen) (Dowsett et al, 2005b). As a
consequence, consideration therefore needs to be given as to why
clear decreases in cellular proliferation at 10–14 days do not
translate into pathological response and why conversely respond-
ing cases can show no change or even an increase in Ki67 with
treatment.
It is possible that lack of correlation in some cases relates in part
to imprecise measurements of proliferation or misclassification of
response. In terms of immunohistochemical assessment of Ki67,
we have already published data on reproducibility in breast cancer
biopsies (Iqbal et al, 2002). These showed that, because of inherent
heterogeneity, marked variation in Ki67 score may be observed in
the same tumour without intervening treatment. However, this is
restricted to occasional tumours, and the number of cases in the
present study with discordance between proliferation changes and
clinical/pathological response is greater than would have been
expected. Furthermore, in order to reduce spurious results, we
have used three different criteria for assessing changes in Ki67. In
terms of the impact of assessment of clinical response, potential
sources of inconsistencies have been considered elsewhere and
vary according to the technology employed (Forouhi et al, 1994).
In the present studies, clinical responses were based primarily
upon ultrasound measurements, but they were substantiated by
parallel calliper and mammographic measurements in all cases.
For ease of presentation, clinical response was dichotomised and it
is possible that the use of continuous variables might have been
more informative. However, preliminary analyses using conti-
nuous variables did not reveal better relationships between
proliferation and response (data not shown). There are also
limitations to the assessment of pathological response in that the
pretreatment assessments (and some of the post-treatment) were
performed on core biopsies, which are not guaranteed to be
representative of the total tumour mass. It is also possible that
assessment of ClinR/PathR at the single time point of 3 months is
associated with chronological inaccuracy in that certain tumours
classified as NR may go on to respond with extended treatment
(Dixon et al, 2005). There is no doubt that response is not
complete by 3 months and treatment up to 12 months may be
associated with (a) further tumour shrinkage and (b) an increased
incidence of complete ClinR.
Although methodological imprecision might be influential in
some cases, it is unlikely that these totally account for the lack of
association between proliferation and response. Other reasons
need to be considered including the possibility that reduction in
proliferation alone may not produce tumour shrinkage and cell
death or apoptosis may be equally influential. Although we have
not measured apoptosis in tumour samples from the present
study (because assessment in core biopsies was not sufficiently
reproducible), we did not find apoptosis to be predictive of
response in other tumour samples from patients offered neoadju-
vant endocrine therapy (Anderson et al, 2002). However, this may
be because differences are small and transient; primary effects on
apoptosis may also be masked by those occurring secondarily (e.g.
as a result of decreased proliferation).
Another cause for a reduction in proliferation at 10–14 days not
translating into subsequent tumour response could be that the
effect is transient and not maintained over a sufficiently extended
period to produce tumour shrinkage. However, in the present
study, four of the five non-responding tumours with a reduction in
Ki67 had a sustained decrease in proliferation to 3 months. A
disconnect between changes in proliferation as observed at 10–14
days with subsequent clinical/pathological response could also be
explained if the proliferation response was delayed. Interestingly,
six of 11 tumours showed a delayed reduction in Ki67 scores; three
of these were classified as PathR/ClinR.
It is worth noting that in 11 of 63 (17%) cases, change in
proliferation at 10–14 days failed to predict that at 3 months.
Furthermore, most importantly, change in proliferation at 10–14
days failed to predict clinical response in 18 out of 63 (29%) cases
and pathological response in 14 out of 62 (23%) tumours. Change
in proliferation at 10–14 days is therefore not an accurate
surrogate of clinical/pathological response at 3 months.
The other marker that showed major changes with therapy was
PgR. Thus, 78% of cases displayed a reduction of at least 1 category
score by 10–14 days and was maintained to 3 months. Reduction
occurred irrespective of subsequent clinical/pathological response.
The extent of effect may be gauged by the percentage of cases
reduced to negativity (40% at 10–14 days and 60% at 3 months);
again the decrease to negativity was irrespective of clinical or
pathological response. As PgR is a marker of signalling from the
ER, these changes are clear evidence of the anti-oestrogenic effects
of letrozole and contrast with those of tamoxifen (Anderson et al,
2002; Miller et al, 2003).
Although we have not formally presented the correlations
between changes in PgR and proliferation, there was a positive
relationship between them. However, there were instances of
discordance whereby at both 10–14 days and 3 months, tumours
displayed either a phenotype of reduced proliferation but stable
PgR or unchanged proliferation and reduced PgR. As reduced PgR
expression is a marker of oestrogen deprivation, it is unlikely that
the lack of effect on Ki67/ClinR/PathR in these cases is because
of lack of aromatase inhibition. Hence, changes in PgR with
treatment, although marked and occurring early, are not predictive
of clinical or pathological response. It was also of interest to
examine changes in PgR score in tumours that initially displayed a
Letrozole, proliferation and response in breast cancer
WR Miller et al
1055
British Journal of Cancer (2006) 94(7), 1051–1056 & 2006 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sdecrease in Ki67 at 10–14 days but an increase at 3 months. This
phenotype could reflect adaptive changes leading to an oestrogenic
stimulation or a state of hypersensitivity to oestrogen (Santen et al,
2004); however, changes in PgR in this cohort of five tumours with
this phenotype revealed three cases that decreased between 10–14
days and 3 months and two cases that were negative at all time
points, providing no evidence for adaptive changes or hypersensi-
tivity to a reduced oestrogenic environment.
In conclusion, the present study has provided evidence that
neoadjuvant letrozole produces marked effects on levels of Ki67
and PgR within 10–14 days. Although early changes in prolifera-
tion are less likely to occur in tumours that show no pathological
response at 3 months, the effects can be seen irrespective of clinical
and/or pathological response in individual cases. Ki67 scores and
PgR expression are therefore of limited value as predictors of
response. They do however reflect the potent anti-oestrogenic and
anti-proliferative properties of the third-generation aromatase
inhibitors and it has been suggested that such changes may relate
to long-term outcome (Ellis et al, 2003; Dowsett et al, 2005b).
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